The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Enhancement of antigen-specific immunity via the TLR4 ligands MPL™ adjuvant and Ribi.529
Abstract
MPL (Corixa) adjuvant is a chemically modified derivative of lipopolysaccharide that displays greatly reduced toxicity while maintaining most of the immunostimulatory activity of lipopolysaccharide. MPL adjuvant has been used extensively in clinical trials as a component in prophylactic and therapeutic vaccines targeting infectious disease, cancer and allergies. With over 33,000 doses administered to date, MPL adjuvant has emerged as a safe and effective vaccine adjuvant. Recently, scientists at Corixa Corporation have developed a library of synthetic lipid A mimetics (aminoalkyl glucosaminide 4-phosphates) with demonstrated immunostimulatory properties. Similar to MPL adjuvant, these synthetic compounds signal through Toll-like receptor 4 to stimulate the innate immune system. One of these compounds, Ribi.529 (RC-529), has emerged as a leading adjuvant with a similar efficacy and safety profile to MPL adjuvant in both preclinical and clinical studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stoute, J. A., Slaoui, M., Heppner, D. G., Momin, P., Kester, K. E., Desmons, P., Wellde, B. T., Garçon, N., Krzych, U., Marchand, M., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701093360202 · Cited by 870
Cited by
Khader, S. A., Bell, G. K., Pearl, J. E., Fountain, J. J., Rangel-Moreno, J., Cilley, G. E., Shen, F., Eaton, S. M., Gaffen, S. L., Swain, S. L., et al. (2007) · Nature Immunology · doi:10.1038/ni1449 · Cited by 1,439
The Vaccine Adjuvant Monophosphoryl Lipid A as a TRIF-Biased Agonist of TLR4
Mata-Haro, V., Cekic, C., Martin, M., Chilton, P. M., Casella, C. R., & Mitchell, T. C. (2007) · Science · doi:10.1126/science.1138963 · Cited by 896
Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists
Kanzler, H., Barrat, F. J., Hessel, E. M., & Coffman, R. L. (2007) · Nature Medicine · doi:10.1038/nm1589 · Cited by 869
Didierlaurent, A. M., Morel, S., Lockman, L., Giannini, S. L., Bisteau, M., Carlsen, H., Kielland, A., Vosters, O., Vanderheyde, N., Schiavetti, F., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901474 · Cited by 758
Putting endotoxin to work for us: Monophosphoryl lipid A as a safe and effective vaccine adjuvant
Casella, C. R., & Mitchell, T. C. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8228-6 · Cited by 560
Steinhagen, F., Kinjo, T., Bode, C., & Klinman, D. M. (2011) · Vaccine · doi:10.1016/j.vaccine.2010.08.002 · Cited by 501
Skeiky, Y. A. W., Alderson, M. R., Ovendale, P. J., Guderian, J. A., Brandt, L., Dillon, D. C., Campos-Neto, A., Lobet, Y., Dalemans, W., Orme, I. M., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.12.7618 · Cited by 313
Coler, R. N., Bertholet, S., Moutaftsi, M., Guderian, J. A., Windish, H. P., Baldwin, S. L., Laughlin, E. M., Duthie, M. S., Fox, C. B., Carter, D., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016333 · Cited by 312
Therapeutics targeting the innate immune system
Ulevitch, R. J. (2004) · Nature Reviews Immunology · doi:10.1038/nri1396 · Cited by 309
Unmet needs in modern vaccinology
Leroux-Roels, G. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.07.021 · Cited by 304
Magnetic Nanoparticles in Targeted Drug Delivery: a Review
kianfar, E. (2021) · Journal of Superconductivity and Novel Magnetism · doi:10.1007/s10948-021-05932-9 · Cited by 280
Baldridge, J. R., McGowan, P., Evans, J. T., Cluff, C., Mossman, S., Johnson, D., & Persing, D. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.7.1129 · Cited by 256
Self-citationEffect of vaccine administration modality on immunogenicity and efficacy
Zhang, L., Wang, W., & Wang, S. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.1081067 · Cited by 255
Prophylactic and therapeutic implications of toll-like receptor ligands
Hedayat, M., Takeda, K., & Rezaei, N. (2012) · Medicinal Research Reviews · doi:10.1002/med.20214 · Cited by 76
Toll-like receptor 4 plays significant roles during allergic rhinitis
Radman, M., Golshiri, A., Shamsizadeh, A., Zainodini, N., Bagheri, V., Arababadi, M. K., & Kennedy, D. (2015) · Allergologia et Immunopathologia · doi:10.1016/j.aller.2014.04.006 · Cited by 39
“adjuvant monophosphoryl lipid A (MPLA) are agonists for TLR4 which are used as adjuvants for the induction of immune responses against vaccination (21-23).”
Metadata
- Authors
- Evans, J. T., Cluff, C. W., Johnson, D. A., Lacy, M. J., Persing, D. H., & Baldridge, J. R.
- Venue
- Expert Review of Vaccines
- Publisher
- Informa UK Limited
- Published
- 2003-04
- Volume
- 2
- Issue
- 2
- Pages
- 219-229
- ISSN
- 1476-0584 (ISSN-L)
- 1744-8395
- OpenAlex
- W1968287338
- Cited by
- 243
- References
- 1
- FWCI
- 3.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.